

0.5, N = 2384), moderate (0.5 < APRI & LE; 1.5, = "" and = "" (apri = "" severe = "" n = "" 377), > 1.5, N = 116). Per patient use and costs of HCV-related medical services and prescriptions were assessed over 12 months post-diagnosis. **RESULTS:** More than 23% of patients with severe HCV had a disease-related hospitalization compared to 12% and 16% of mild and moderate patients, respectively (both $P < 0.05$). Hospitalization costs were nearly 2.5 times higher in moderate patients (\$3480) and approximately 4.7 times higher in severe patients (\$6872) compared to those with mild disease (\$1448; both $P < 0.01$). Severe patients also had a significantly ($P < 0.01$) higher mean number of hospital days (7.9) compared to moderate (6.7 days) and mild patients (4.1 days). There were no significant differences in encounters and costs for physician office and emergency department visits. Severe patients had slightly lower (but insignificant) HCV-related pharmacy costs compared to mild and moderate patients. After controlling for demographics and comorbidities in a multivariate analysis, mild patients incurred \$4708 less ($P < 0.01$) in total HCV-related costs compared to severe patients. **CONCLUSIONS:** Patients with moderate and severe HCV incur nearly twice the medical costs of patients with mild disease, due primarily to increased hospitalizations. There was no significant difference in ambulatory resource use and costs between moderate and severe patients.

EE4

CAREER INTERRUPTIONS AND SICK LEAVES AMONG FIBROMYALGIA PATIENTS

Le Lay K¹, Boussetta S¹, Moldofsky H², Taieb C¹

¹Pierre Fabre, Boulogne, France, ²Centre for Sleep and Chronobiology, Toronto, ON, Canada

OBJECTIVES: Early diagnosis of fibromyalgia and its management represent a public health issue for the health authorities who allocate resources. Career interruptions and absences from work consume a significant share of these resources. The aim was to describe the characteristics of subjects who reported career interruptions or sick leaves in UK, **METHODS:** Four questionnaires, the LFESSQ (London Fibromyalgia Epidemiology Study Screening Questionnaire), the CES-D (Center for Epidemiologic Studies Depression Scale), the SQA (Sleep Quality Assessment), and the FMQ (Fibromyalgia Moldofsky Questionnaire), were administered to a representative community sample in UK. A descriptive analysis of career interruptions and sick leaves was carried out using social and demographic data and symptoms supplied by the subjects surveyed, **RESULTS:** 25.1% stated that they were not working at the time of the survey, with significantly more women (34.3% vs 15.5%), subjects over 50 (50.5% vs 4.9%) and with a low income (58.2% vs 45.9%). Subjects with pain (LFESSQ positive), a strong presumption of fibromyalgia syndrome (FMQ > 8), with an unrestorative sleep (SQA ≥ 14), a possible depressive symptoms (CES-D > 17) were significantly more frequently inactive. 24.8% had been absent during the last year (average of 8.6 absence days). Subjects with pain, a strong presumption of fibromyalgia, an unrestorative sleep, a possible depressive symptoms were not more frequently absent from work. The number of absence days increased significantly with the number of concomitant symptoms: 1 day for subjects experiencing pain, 1.8 for subjects with a sleep disorder, 3.3 for pain and fatigue, 3.8 for pain and probable depressive symptoms, reaching 5.1 days for a combination of pain, fatigue and probable depressive symptoms, **CONCLUSIONS:** Career interruptions were significantly more common in subjects who screened positive on the LFES-SQ and who had a strong presumption of fibromyalgia syndrome, whereas absence from work mostly affected subjects with a sleep disorder.

PODIUM SESSION I: MEDICAL DEVICE ECONOMIC EVALUATIONS

MDI

HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE I DIABETES IN POLAND

Clegg JP¹, Wéry E¹, Karamalis M², Pokorski J², Mlynarski W³, Valentine WJ¹

¹IMS Health, Allschwil, Switzerland, ²Medtronic Poland Sp. z o.o. Warsaw, Poland, ³Medical University of Lodz, Lodz, Poland

OBJECTIVES: To evaluate the long-term clinical and economic outcomes of treating adults and adolescents with type 1 diabetes with continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in Poland. **METHODS:** A validated model was used to estimate the lifetime impact of CSII-related improvements in diabetes control on quality-adjusted life-expectancy (QALE), occurrence of complications, and direct medical costs in two Polish type 1 diabetes cohorts (Adult—mean age 37.8 years, duration of diabetes 10.4 years, mean HbA1c 9.40%; adolescent—mean age 14.0 years, duration of diabetes 1.0 year, mean HbA1c 9.40%, no baseline complications). Treatment effects of CSII were defined from a meta-analysis as a reduction of 0.95% in HbA1c and a decrease in severe hypoglycemia (14.8 versus 62 events per 100 patient-years) compared with MDI. Future costs and benefits were discounted at 5% annually and projected over the patient's lifetime. All costs were evaluated in 2006 Polish Zloty and converted to Euro (€). **RESULTS:** CSII was associated with improvements in QALE (0.35 and 0.46 quality-adjusted life-years [QALYs] for adults and adolescents, respectively) and fewer diabetes-related complications versus MDI. Over patient's lifetime CSII versus MDI for adults and adolescents was projected to reduce the cost of renal disease by €865 and €413 and cost of hypoglycaemia by €576 and €3,463, respectively. For adults and adolescents CSII was projected to cost €9,309 and €19,294 more than MDI over a patient's lifetime, respectively. CSII was associated with an incremental cost-effectiveness ratio (ICER) of €20,778 for adults and €14,968 for adolescents per QALY gained versus MDI. **CONCLUSIONS:** Based on the threshold proposed by the World Health Organization (4 times the Gross Domestic Product per capita, approximately €26,000), CSII treatment improves clinical outcomes and represents a cost-effective treatment option compared with MDI for patients with type 1 diabetes in Poland.

MD2

(For MD2 see page A419)

WITHDRAWN